NASDAQ:AMRN - Nasdaq - US0231114044 - ADR - Currency: USD
Taking everything into account, AMRN scores 3 out of 10 in our fundamental rating. AMRN was compared to 562 industry peers in the Biotechnology industry. AMRN has a great financial health rating, but its profitability evaluates not so good. AMRN is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -11.99% | ||
ROE | -16.9% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 51.55% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 10.2 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.31 | ||
Quick Ratio | 2.39 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
10.15
-0.12 (-1.17%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 18.39 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 8.65 | ||
P/tB | 8.95 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -11.99% | ||
ROE | -16.9% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 51.55% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 3.31 | ||
Quick Ratio | 2.39 | ||
Altman-Z | 10.2 |